Improved next generation of T-cell redirecting bispecific antibodies enters clinical proof-of-concept phase
- Category: Press Room
- Published on Friday, 13 May 2016 11:09
- Hits: 6061
STUTTGART, Germany I May 13, 2016 I Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields in cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.
Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months. Data from these clinical studies in the next years will give valuable feedback for the further design of T-cell redirecting bispecific constructs.
In a new report released by La Merie Publishing, the competitive T-cell redirecting bispecific antibody stakeholders, technologies, pipelines and deals is described and analyzed.
This report „T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals“ provides up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.
The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.
Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.
The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing